These results suggest that Q702 not only enhances the antitumor efficacy of anti-PD-1 antibody but can also overcome the limited efficacy of anti-PD-1 by enhancing tumor immunogenicity and inducing CD8 T cell infiltration into the TME. This evidence concerns the gene CD8A and neoplasm.